398 related articles for article (PubMed ID: 23659971)
1. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
[TBL] [Abstract][Full Text] [Related]
2. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Suzuki K; Ogura M; Abe Y; Suzuki T; Tobinai K; Ando K; Taniwaki M; Maruyama D; Kojima M; Kuroda J; Achira M; Iizuka K
Int J Hematol; 2015 Mar; 101(3):286-94. PubMed ID: 25655379
[TBL] [Abstract][Full Text] [Related]
6. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M; Qin X; Herring J; Casper C; Kurzrock R
J Clin Oncol; 2010 Aug; 28(23):3701-8. PubMed ID: 20625121
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
8. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Gercheva L; Williams C; Sutherland H; Robak T; Masszi T; Goranova-Marinova V; Dimopoulos MA; Cavenagh JD; Špička I; Maiolino A; Suvorov A; Bladé J; Samoylova O; Puchalski TA; Reddy M; Bandekar R; van de Velde H; Xie H; Rossi JF
Am J Hematol; 2015 Jan; 90(1):42-9. PubMed ID: 25294016
[TBL] [Abstract][Full Text] [Related]
9. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
10. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
11. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
Hudes G; Tagawa ST; Whang YE; Qi M; Qin X; Puchalski TA; Reddy M; Cornfeld M; Eisenberger M
Invest New Drugs; 2013 Jun; 31(3):669-76. PubMed ID: 22828917
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
16. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
Patel M; Ikeda S; Pilat SR; Kurzrock R
JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
